LIES: How the All-In Podcast Lied Again [Cancer Vaccine].

Meet Kevin

35,368 views • 3 days ago Save 17 min 6 min read

Video Summary

David Friedberg on the "All In" podcast sparked controversy by claiming that a new cancer therapy breakthrough from Moderna and Merck is a "nothing burger," easily replicated by unregulated labs for a fraction of the cost. However, the speaker argues Friedberg fundamentally misunderstands the science, conflating two distinct approaches to cancer treatment. Friedberg suggests that paying $50,000 for a compounded neoantigen peptide therapy is equivalent to Moderna's FDA-approved mRNA therapy, which could cost $500,000.

The core of the argument lies in how these therapies engage the immune system. Moderna's approach uses mRNA to instruct dendritic cells to present custom neoantigens to the immune system, activating a broad response including "hunters" (CD8+ T cells) crucial for fighting internal threats like metastatic cancer. Friedberg, conversely, implies that simpler injected peptides can achieve the same result, potentially only activating "town guards" (CD4+ T cells) and failing to address the internal, mutated nature of cancer. The speaker emphasizes that the complexity, AI-driven customization, and comprehensive immune activation of the FDA-approved therapy are what justify its cost and differentiate it from less regulated, potentially less effective alternatives.

Short Highlights

A recent phase three trial for a cancer therapy by Moderna and Merck met its primary endpoint, significantly reducing melanoma recurrence.
David Friedberg on the "All In" podcast dismissed the breakthrough, claiming unregulated compounding labs can offer similar treatments for $50,000, calling the FDA-approved therapy a "nothing burger."
The speaker refutes Friedberg's claims, arguing he misunderstands the fundamental biomechanics of the therapies.
Moderna's therapy uses custom mRNA to activate dendritic cells, which then present neoantigens to the immune system, activating both "town guards" (CD4+ T cells) and "hunters" (CD8+ T cells) to combat internal cancer threats.
Friedberg's suggested alternative involves injecting peptides directly, which the speaker contends may only activate "town guards" and is less effective against metastatic cancer.
The complexity of Moderna's approach, including AI-driven customization for up to 32 mutations and comprehensive immune activation, differentiates it from simpler peptide injections.
The speaker suggests Friedberg's critique may stem from oversimplification or a misunderstanding of the advanced science involved, potentially leading to a disservice to the audience.

Key Details

The Cancer Breakthrough and Friedberg's Critique [0:00]

A phase three trial for a cancer therapy, a partnership between Moderna and Merck, has met its primary endpoint by significantly reducing melanoma recurrence.
This therapy, an mRNA-based treatment, is presented as a potential first phase three cancer therapy aimed at preventing recurrence.
David Friedberg on the "All In" podcast dismisses this breakthrough, suggesting that unregulated compounding labs can provide similar results for $50,000, labeling the FDA-approved therapy a "nothing burger."
"This is a big nothing burger."

Misunderstanding of Therapy Mechanics [0:49]

Friedberg argues that people can pay $50,000 to have custom neoantigens made by compounding labs, implying this is equivalent to the expensive FDA-approved drug.
He expresses frustration that Moderna might charge $500,000 for a therapy that he believes can be obtained much cheaper through alternative means.
The speaker contends that Friedberg fundamentally misexplains how these therapies work and conflates different approaches.
"The process is take the DNA sequence from my cancer, make a protein, put it back in my body. My immune system goes and destroys the cancer in my body."

The Role of Dendritic Cells [2:48]

The explanation focuses on dendritic cells, which absorb foreign particles and present them as signaling tools.
Moderna's approach involves encapsulating custom mRNA instructions within lipid nanoparticles, which dendritic cells can absorb.
These dendritic cells then process the mRNA and display custom proteins on their surface, acting as messengers.
"And its job is basically to look for foreign particles in your body and just absorb them."

Injected Peptides vs. mRNA Instructions [3:30]

The speaker highlights a critical difference: Moderna's mRNA therapy involves dendritic cells processing internal instructions, whereas Friedberg's suggestion implies directly injecting peptides.
Directly injecting peptides may not be as effective as the mRNA approach, where the body's own cells process and present the antigens.
Moderna's mRNA instructions can carry information about approximately 32 mutations, while BioNTech's carry about 18-20.
"The process of this dendritic cell absorbing this entire MRNA is very different than coming in and just saying, Hey, why don't we just inject the peptide directly?"

Immune System Activation: Town Guard vs. Hunters [4:45]

Dendritic cells migrate to the lymphatic system to present processed information to immune cells.
Friedberg's argument is criticized for oversimplifying this process, suggesting that activating the "town guard" (CD4+ T cells) for $50,000 is sufficient.
The speaker explains that Moderna's therapy activates a broader immune response, including the "hunters" (CD8+ T cells), which are crucial for targeting internal threats like metastasized cancer.
"This is a really fancy way of saying a lot more of your immune system than you end up getting activated if you only have these little green activated peptides from the injection."

The Stakes of Metastasis [6:10]

The speaker contrasts the "external army" activation from simple injections with the activation of both "external" and "internal" armies by the mRNA therapy.
This comprehensive activation is linked to a significantly lower risk of cancer spread (metastasis) in trials, potentially reducing it by over 59%.
Friedberg's conflation of the two approaches ignores the critical difference in how they combat the internal nature of cancer.
"And as a result, you get 59% plus, at least this in the trials, less spread or less metastasis."

The Role of AI in Customization [8:00]

The development of these custom cancer therapies is significantly accelerated by Artificial Intelligence.
AI helps identify critical tumor mutations and predict which protein sequences will effectively fold and be recognized by the immune system.
Previously, identifying a single target mutation could take 60 days; AI allows for the selection of multiple mutations (e.g., 32 for Moderna) in hours.
"The research that, or what Friedberg suggests is like, hey, this is just, this is a process anybody can do."

Why the High Cost and Complexity Matter [10:15]

The speaker argues that the value lies not just in the process but in the sophisticated application, including AI-driven customization and rigorous FDA approval.
This complex, human-involved process of training and adjusting AI models is what creates a durable and effective product, unlike simply plugging data into a basic chatbot.
Friedberg's assertion that the process is easily replicable overlooks the significant research, development, and regulatory hurdles overcome by companies like Moderna.
"And that's a human involved process. I think the same is true at Moderna and these companies coming up with cancer vaccines."